Abstract
Liver disease continues to be one of the leading causes of hospitalization and death in HIV-infected individuals. Important etiologies include both alcoholic and non-alcoholic steatohepatitis, and coinfection with hepatitis viruses B and C. While non-alcoholic fatty liver disease is increasingly diagnosed in this population, most cases of chronic hepatitis B can be well controlled with tenofovir-based regimens, and hepatitis C has entered a revolutionary era in which most patients may be cured with direct-acting antivirals. However, important gaps remain unaddressed. Hepatitis delta is a neglected disease, despite 15 million people being infected worldwide, and represents the most severe form of viral hepatitis. Hepatitis E is largely unrecognized, despite being the major cause of acute viral hepatitis worldwide and occasionally leading to chronicity in immunosuppressed individuals.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy
-
AIDS-Related Opportunistic Infections / epidemiology*
-
AIDS-Related Opportunistic Infections / immunology
-
Anti-HIV Agents / therapeutic use
-
Antiviral Agents / therapeutic use
-
Coinfection
-
Disease Progression
-
End Stage Liver Disease / drug therapy
-
End Stage Liver Disease / epidemiology*
-
End Stage Liver Disease / immunology
-
Fatty Liver / drug therapy
-
Fatty Liver / epidemiology*
-
Fatty Liver / immunology
-
Female
-
HIV Infections / drug therapy
-
HIV Infections / epidemiology*
-
HIV Infections / immunology
-
Hepatitis B / epidemiology
-
Hepatitis C / epidemiology
-
Hepatitis D / epidemiology
-
Hepatitis, Viral, Human / drug therapy
-
Hepatitis, Viral, Human / epidemiology*
-
Hepatitis, Viral, Human / immunology
-
Humans
-
Immunocompromised Host
-
Male
Substances
-
Anti-HIV Agents
-
Antiviral Agents